RxDoctor Payments Data

Roshani Kandel

Primary Care · Council Bluffs, IANPI 1053095802

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $214 and has fallen 93.0% since, to $15 in 2025. That places this record below the midpoint for primary care clinicians in IA, where the typical reported total is $294.

$285in general payments, 2019–2025

Across 15 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$59
  • Johnson & Johnson$52
  • Lundbeck LLC$33
  • Teva Pharmaceuticals USA, Inc.$29
  • Exact Sciences$28
  • Vanda Pharmaceuticals Inc.$20
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$285 in reported general payments places this provider in the 45th percentile of 36 primary care providers in Iowa.

See all primary care providers in Iowa

Medicare billing

Part B allowed, 2024
$380
Medicare patients
17
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$78,092
JardianceEmpagliflozin71$62,961
TrulicityDulaglutide33$46,954
MounjaroTirzepatide26$26,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,003
XareltoRivaroxaban23$14,246
Albuterol Sulfate HfaAlbuterol Sulfate53$1,344
Ventolin HfaAlbuterol Sulfate20$1,337
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,092
Midodrine Hcl11$784
Gabapentin74$704
Diclofenac Sodium22$650
Atorvastatin Calcium138$562
Levothyroxine Sodium56$391
Lisinopril76$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$14$73,71159 claims
Johnson & JohnsonXarelto$52$14,24623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 36 primary care providers in Iowa.

Other primary care in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →